Alaleh Nouri Sells 3,243 Shares of PROCEPT BioRobotics (NASDAQ:PRCT) Stock

PROCEPT BioRobotics Corporation (NASDAQ:PRCT) EVP Alaleh Nouri sold 3,243 shares of the company’s stock in a transaction on Tuesday, March 10th. The stock was sold at an average price of $25.65, for a total transaction of $83,182.95. Following the completion of the transaction, the executive vice president directly owned 111,021 shares of the company’s stock, valued at $2,847,688.65. This represents a 2.84% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this link.

Alaleh Nouri also recently made the following trade(s):

• On Friday, March 6th, Alaleh Nouri sold 6,892 shares of PROCEPT BioRobotics stock. The shares were sold at an average price of $23.70, for a total value of $163,340.40.

PROCEPT BioRobotics Price Performance

Shares of NASDAQ PRCT traded down $1.73 during mid-day trading on Thursday, reaching $26.07. The company’s stock had a trading volume of 1,278,156 shares, compared to its average volume of 1,693,463. The company has a debt-to-equity ratio of 0.14, a current ratio of 6.85 and a quick ratio of 5.77. PROCEPT BioRobotics Corporation has a 52 week low of $19.35 and a 52 week high of $66.85. The stock has a fifty day moving average of $28.89 and a two-hundred day moving average of $32.68. The firm has a market capitalization of $1.47 billion, a PE ratio of -15.24 and a beta of 1.02.

PROCEPT BioRobotics (NASDAQ:PRCT) last posted its quarterly earnings results on Wednesday, February 25th. The company reported ($0.53) EPS for the quarter, missing analysts’ consensus estimates of ($0.32) by ($0.21). PROCEPT BioRobotics had a negative return on equity of 25.13% and a negative net margin of 31.02%.The business had revenue of $76.38 million during the quarter, compared to analysts’ expectations of $93.70 million. During the same period in the prior year, the firm posted ($0.35) earnings per share. The firm’s revenue for the quarter was up 11.9% on a year-over-year basis. As a group, sell-side analysts anticipate that PROCEPT BioRobotics Corporation will post -1.75 EPS for the current fiscal year.

Analysts Set New Price Targets

Several research analysts have commented on PRCT shares. Weiss Ratings reissued a “sell (e+)” rating on shares of PROCEPT BioRobotics in a report on Thursday, January 22nd. UBS Group started coverage on PROCEPT BioRobotics in a report on Friday, December 12th. They set a “buy” rating and a $62.00 price target for the company. Robert W. Baird began coverage on PROCEPT BioRobotics in a report on Friday, March 6th. They set a “neutral” rating and a $30.00 price objective on the stock. Bank of America lowered shares of PROCEPT BioRobotics from a “neutral” rating to an “underperform” rating and cut their target price for the company from $38.00 to $20.00 in a report on Thursday, February 26th. Finally, Wells Fargo & Company decreased their price target on shares of PROCEPT BioRobotics from $51.00 to $34.00 and set an “overweight” rating on the stock in a research note on Thursday, February 26th. Eight analysts have rated the stock with a Buy rating, four have issued a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average target price of $40.82.

Institutional Trading of PROCEPT BioRobotics

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Prosight Management LP boosted its stake in PROCEPT BioRobotics by 1,692.4% during the fourth quarter. Prosight Management LP now owns 1,380,000 shares of the company’s stock worth $43,415,000 after buying an additional 1,303,009 shares during the period. Alliancebernstein L.P. lifted its holdings in shares of PROCEPT BioRobotics by 58.6% in the 3rd quarter. Alliancebernstein L.P. now owns 3,419,784 shares of the company’s stock worth $122,052,000 after acquiring an additional 1,262,928 shares during the last quarter. T. Rowe Price Investment Management Inc. boosted its stake in shares of PROCEPT BioRobotics by 59.4% during the 4th quarter. T. Rowe Price Investment Management Inc. now owns 3,271,408 shares of the company’s stock worth $102,919,000 after purchasing an additional 1,218,815 shares during the period. Chicago Capital LLC grew its holdings in PROCEPT BioRobotics by 175.7% during the 3rd quarter. Chicago Capital LLC now owns 1,568,845 shares of the company’s stock valued at $55,992,000 after purchasing an additional 999,873 shares during the last quarter. Finally, Westfield Capital Management Co. LP raised its position in PROCEPT BioRobotics by 113.5% in the 2nd quarter. Westfield Capital Management Co. LP now owns 1,598,349 shares of the company’s stock worth $92,065,000 after purchasing an additional 849,792 shares during the period. Hedge funds and other institutional investors own 89.46% of the company’s stock.

About PROCEPT BioRobotics

PROCEPT BioRobotics, Inc is a medical device company specializing in the development and commercialization of robotic systems for the treatment of benign prostatic hyperplasia (BPH). The company’s technology leverages precision robotics and real-time imaging to perform minimally invasive procedures, aiming to reduce patient recovery time and improve clinical outcomes compared to traditional surgical approaches.

The company’s flagship product, the AquaBeam Robotic System, uses a high-velocity waterjet to selectively remove prostate tissue while preserving surrounding healthy structures.